P1, N=7, Active, not recruiting, Tianjin Medical University Cancer Institute and Hospital | Recruiting --> Active, not recruiting | N=10 --> 7 | Trial completion date: Oct 2022 --> Dec 2023 | Trial primary completion date: Jul 2022 --> Jul 2023
11 months ago
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
P1, N=25, Active, not recruiting, Shanghai Tongji Hospital, Tongji University School of Medicine | Recruiting --> Active, not recruiting | Trial completion date: Aug 2021 --> Dec 2023 | Trial primary completion date: Aug 2021 --> Jun 2023
12 months ago
Enrollment closed • Trial completion date • Trial primary completion date
C-CAR039 was administered as a single intravenous dose after a 3-day cyclophosphamide plus fludarabine conditioning regimen . C-CAR039 demonstrated a favorable safety profile and promising efficacy in this early clinical trial in patients with r/r B-NHL that might allow it to differentiate from existing therapies . The early clinical efficacy signal is encouraging and compares favorably to anti-CD19 CAR-T and peer therapies . These findings will be evaluated in more patients with longer follow-up to confirm safety, efficacy and duration of response.